下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
01801 信达生物
24.050
-1.350-5.31%
显示同比
不显示
隐藏空行
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Per Share IndicaTor
Operating Cash Flow Per Share
-- -- -549.94% -1.6938 -38.05% -0.8368 82.29% -0.2606
Cash Flow Per Share
-- -- 147.73% 0.2345 568.56% 2.6956 73.84% -0.4914
Operating Income Per Share
11.53% 1.7846 9.71% 3.5717 99.46% 1.6001 251.51% 3.2557
Net Asset Per Share
-22.1% 7.6426 16.21% 8.6416 87.93% 9.8103 76.84% 7.4365
Basic Earning Per Share
21.92% -0.7601 -200.47% -2.6419 -93.3% -0.9735 46.05% -0.8792
Diluted  Earning Per Share
21.92% -0.7601 -200.47% -2.6419 -93.3% -0.9735 46.05% -0.8792
Profitability
Gross Profit Ratio
-10.2% 78.946% -3.71% 86.579% 8.23% 87.910% 2.08% 89.912%
Operating Profit Ratio
27.93% -42.612% -240.41% -69.994% -1.72% -59.125% 87.03% -20.562%
Net Profit Ratio
29.89% -42.439% -182.95% -73.495% 2.05% -60.528% 84.18% -25.975%
Earning Before Tax Ratio
26.3% -44.602% -219.86% -71.457% 1.49% -60.521% 86.39% -22.340%
ROE
18.38% -9.320% -120.79% -33.278% -5.65% -11.419% 60.33% -15.072%
ROA
31.31% -5.734% -111.06% -22.624% -12.06% -8.348% 57.95% -10.719%
Yield Quality
Operating Cash To Total Revenue
-- -- -492.44% -47.423% 30.78% -52.295% 94.96% -8.005%
Capital Structure
Debt Assets Ratio
46.96% 40.644% 41.02% 36.404% -2.87% 27.656% -24.56% 25.815%
Equity Multipler
21.88% 1.6848 16.65% 1.5724 -1.13% 1.3823 -11.33% 1.348
Debt Equity Ratio
79.12% 68.475% 64.5% 57.242% -3.97% 38.229% -33.11% 34.798%
Current Assets To tatal Assets
-15.12% 69.279% -11.1% 71.110% 2.04% 81.624% 6.02% 79.989%
Non Current Assets To Total Assets
67.18% 30.721% 44.37% 28.890% -8.17% 18.376% -18.49% 20.011%
Current Liabilities To tatal Liabilities
7.63% 53.015% 6.06% 51.579% 15.76% 49.255% 15.31% 48.633%
Non Current Liabilities To Total Liabilities
-7.41% 46.985% -5.74% 48.421% -11.67% 50.745% -11.17% 51.367%
Solvency
Current Ratio
-46.34% 3.2152 -40.56% 3.7871 -9.24% 5.992 21.87% 6.3712
Quick Ratio
-49.26% 2.791 -43.26% 3.3454 -10.87% 5.5006 20.72% 5.8963
Operating Profit To Current Liabilities
46.48% -0.2741 -84.21% -0.9798 2.88% -0.5121 66.57% -0.5319
Operrating Cash Flow To Current Liabilities
-- -- -220.59% -0.6639 33.91% -0.453 87.02% -0.2071
Share Equity Without Minority Interest To Total Liabilities
-44.17% 1.4604 -39.21% 1.747 4.14% 2.6158 49.5% 2.8737
Operating Cash Flow To Total Liabilities
-- -- -240.01% -0.3424 23.5% -0.2231 85.03% -0.1007
Operating Profit To Total Liabilities
42.39% -0.1453 -95.37% -0.5054 -12.43% -0.2523 61.45% -0.2587
Operating Capacity
Inventory Turnover(T)
25.22% 0.3268 -24.2% 0.5638 -41.21% 0.2609 26.98% 0.7438
Current Assets Turnover(T)
12.94% 0.1924 -21.87% 0.4116 10.15% 0.1704 157.94% 0.5268
Fixed Assets Turnover(T)
-28.57% 0.7753 -25.25% 2.0179 52.38% 1.0855 215.65% 2.6997
Total Assets Turnover(T)
-2.03% 0.1351 -25.41% 0.3078 14.4% 0.1379 165.81% 0.4127
Growth Ability
Operating Revenue GR 3Y
-98.72% 566.735% 135.11% 48182.728% 378.32% 44252.263% -- 20493.644%
Gross Income GR 3Y
-- 497.134% -- -- -- -- -- --
Operating Profit GR 3Y
99.03% -44.857% 334.05% 44.818% -3570.66% -4611.839% 91.95% -19.149%
EBT GR 3Y
97.77% -43.825% 331.99% 44.327% -1635.5% -1967.369% 91.13% -19.107%
Net Profit GR 3Y
98.13% -36.850% 211.05% 42.738% -1616.88% -1967.636% 82.14% -38.485%
Net Profit Attributable To The Parent Company GR 3Y
98.69% -36.850% 154.66% 41.731% -1469.51% -2813.072% 68.27% -76.346%
Total Assets GR 3Y
-18.31% 196.649% -51.07% 184.123% -- 240.726% 139.98% 376.303%
Share Equity Without Minority Interest GR 3Y
-79.26% 179.702% -70.14% 163.324% -- 866.444% 23.27% 546.961%
Equity GR 3Y
-79.26% 179.702% -74.29% 163.324% -- 866.444% 6.51% 635.250%
Total Liabilities GR 3Y
885.54% 225.445% 985.29% 229.602% -- -28.699% 24.67% -25.935%
Basic Earning Per Share GR 3Y
97.9% -7.839% -1.25% 86.573% -557.61% -373.576% 12.67% 87.668%
Net Assets Per Share GR 3Y
-- 120.529% -- 107.763% -- -- -- --
Other Indicators
Currency Unit
港元港元港元港元

Q6、Q9、FY为累计季报:Q6 为中期报告;Q9 为第三季报;FY为年报。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
信达生物制药是一家主要从事生物制药的投资控股公司。该公司及其子公司从事抗体及蛋白质医药产品的研发、药品的销售及分销,以及提供咨询及研发服务。该公司的主要产品为达伯舒(信迪利单抗注射液),用于治疗复发或难治性经典霍奇金淋巴瘤。该公司的产品还包括阿达木单抗生物类似药IBI-303,用于治疗类风湿性关节炎、强直性脊柱炎及银屑病。贝伐珠单抗生物类似药IBI-305,用于治疗转移性结直肠癌及晚期、转移性或复发性非小细胞肺癌(NSCLC)。利妥昔单抗生物类似药IBI-301,用于治疗非霍奇金淋巴瘤及慢性淋巴细胞白血病。该公司的产品应用于肿瘤、代谢、免疫学及眼底病等领域。
董事长: 俞德超
所属市场: 香港主板
上市日期: 2018/10/31
富途热股榜
港股美股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部